Protocol list

Protocol List

The Protocol List provides a listing of NCI clinical trials that are supported by the CTSU and are either active, near activation or temporarily closed. The list may be sorted by Protocol Number, Lead Organization, NIH Program, Status, or Phase. Clicking to the right of each title in the header row will display an arrow, an upwards facing arrow will sort by ascending order and a downwards facing arrow will display by descending order. Each protocol number is hyperlinked and clicking on the protocol number will open a new website, the National Cancer Institute’s Clinical Trials Physicians Data Query (PDQ®). PDQ provides additional information about each clinical trial including the trial summary, eligibility criteria and a listing of sites that have the trial open. The protocol list can be exported to and Excel or CSV file or printed by selecting the icon located above the header row.

Phase:

ALL

NIH Program:

ALL

Disease:

ALL

Keyword:

*Some accruals have occurred outside of the CTSU systems and are collected manually, thus the total accrual number may not be accurate.

#	Protocol Number	Lead Organization	NIH Program	Disease	Status	Protocol Title	Phase	Accrual Target	Accrual Total
Export Excel (CSV) Refresh 1 1 2 3 4 5 6 255
Page 1 of 6 Last update: 9:59:59 AM UTC
1	EAY131-J	ECOG-ACRIN	NCTN	N/A	Active	MATCH Treatment Subprotocol J; Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers, and Non-Colorectal Cancers with HER2 Amplification		0	0
2	EAY131-Z1C	ECOG-ACRIN	NCTN	N/A	Temporarily Closed to Accrual	MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification		0	0
3	N0577	ALLIANCE	NCTN	CNS Cancer (Primary tumor)	Active	N0577 (CODEL): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma	III	361	141
4	RTOG-0724	NRG	NCTN	Female Reproductive System Cancer	Active	Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy	III	285	192
5	GOG-0263	NRG	NCTN	Female Reproductive System Cancer	Active	Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)	III	534	297
6	EAY131-S2	ECOG-ACRIN	NCTN	N/A	Active	MATCH Treatment Subprotocol S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 Mutations		0	0
7	CALGB-30610	ALLIANCE	NCTN	Lung, Mediastinal, and Pleural Cancer	Active	Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide	III	729	694
8	EAY131-E	ECOG-ACRIN	NCTN	N/A	Active	MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR		0	0
9	EAY131-G	ECOG-ACRIN	NCTN	N/A	Active	MATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients with ROS1 Translocations (Other Than Patients with Non-Small Cell Lung Cancer)		0	0
10	EAY131-Z1E	ECOG-ACRIN	NCTN	N/A	Active	MATCH Treatment Subprotocol Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions		0	0
11	EAY131-Z1G	ECOG-ACRIN	NCTN	N/A	Active	MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and Any PTEN Sequencing Result		0	0
12	EAY131-V	ECOG-ACRIN	NCTN	N/A	Active	Match Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuorendocrine Tumor)		0	0
13	EAY131-F	ECOG-ACRIN	NCTN	N/A	Active	MATCH Treatment Subprotocol F: Crizotinib in Patients with Tumors (other Than Adenocarcinoma of Lung or ALCL) with ALK Rearrangements		0	0
14	EAY131-Z1F	ECOG-ACRIN	NCTN	N/A	Temporarily Closed to Accrual	MATCH Treatment Subprotocol Z1F: Phase II Study of Copanlisib in Patients with Tumors with PIK3CA Mutations (PTEN Loss Allowed)		0	0
15	A231701CD	ALLIANCE	NCORP	Breast Cancer	Pre-Activation	Increasing Socioeconomically Disadvantaged Patients' Engagement in Breast Cancer Surgery Decision Making Through a Shared Decision Making Intervention	Other	1050	0
16	EAY131-C1	ECOG-ACRIN	NCTN	N/A	Temporarily Closed to Accrual	MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification		0	0
17	EAY131-A	ECOG-ACRIN	NCTN	N/A	Active	EAY131-A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment		0	0
18	EAY131-M	ECOG-ACRIN	NCTN	N/A	Active	MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (Tak-228) in Patients with Tumors with TSC1 or TSC2 Mutations		0	0
19	EAY131-T	ECOG-ACRIN	NCTN	N/A	Active	MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations		0	0
20	EAY131-L	ECOG-ACRIN	NCTN	N/A	Active	MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors wtih mTOR Mutations		0	0
21	EAY131-K1	ECOG-ACRIN	NCTN	N/A	Active	MATCH Treatment Subprotocol K1: Phase II Study of Erdafitinib (JNJ-42756493) in Patients with Tumors with FGFR Amplifications		0	0
22	EAY131-K2	ECOG-ACRIN	NCTN	N/A	Active	MATCH Treatment Subprotocol K2: Phase II Study of Erdafitinib (JNJ-42756493) in Patients with Tumors with FGFR Mutations and Fusions		0	0
23	EAY131-C2	ECOG-ACRIN	NCTN	N/A	Active	MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion		0	0
24	EAY131-Z1H	ECOG-ACRIN	NCTN	N/A	Active	MATCH Treatment Subprotocol Z1H: Phase II Study of Copanlisib in Patients with Tumors with Deleterious PTEN Sequencing Result and PTEN Expression by IHC		0	0
25	PBTC-049	PBTC	MISCELLANEOUS	CNS Cancer (Primary tumor)	Active	A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Primary CNS Tumors	I	36	2
26	PBTC-051	PBTC	MISCELLANEOUS	CNS Cancer (Primary tumor)	Active	Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma	I	45	9
27	S1600	SWOG	NCORP	Urothelial/ Bladder Cancer	Pre-Activation	A Randomized Phase III Double Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes	III	200	0
28	URCC-16092	URCC	NCORP	Gastrointestinal Cancer	Active	Phase II Study of Low-Dose Ibuprofen for Cognitive Impairment in Colorectal Cancer Patients Receiving Chemotherapy	II	86	0
29	EAY131-Z1I	ECOG-ACRIN	NCTN	N/A	Temporarily Closed to Accrual	MATCH Treatment Subprotocol Z1I: Phase II Study of AZD1775 in Patients with Tumors Containing BRCA1 and BRCA2 Mutations		0	0
30	10106	LAO-MD017	ETCTN	Lymphoma	Active	A Phase I and Randomized Phase II Study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in Relapsed and Refractory Lymphomas	I/II	76	1
31	10150	LAO-11030	ETCTN	Female Reproductive System Cancer	Active	A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer	I/II	96	7
32	10145	LAO-NCI	ETCTN	Lymphoma;Miscellaneous and Metastatic Cancer	Active	Phase Ib Combination Study of Copanlisib and Nivolumab in Advanced Solid Tumors and Lymphomas	I	41	7
33	EA8171	ECOG-ACRIN	NCTN	Male Reproductive System Cancer	Active	Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer	II	852	0
34	A021602	ALLIANCE	NCTN	Endocrine Cancer	Active	Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Everolimus (CABINET)	III	395	6
35	10166	LAO-MD017	ETCTN	Lung, Mediastinal, and Pleural Cancer	Active	A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer	II	24	1
36	S1703	SWOG	NCORP	Breast Cancer	Active	Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer	Other	1320	13
37	S1712	SWOG	NCTN	Leukemia	Active	A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease	II	84	2
38	AGCT1532	COG	NCTN	Germ Cell Cancer	Active	A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Germ Cell Tumors	III	150	5
39	A031701	ALLIANCE	NCTN	Urothelial/ Bladder Cancer	Active	A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations	II	271	2
40	A211601	ALLIANCE	NCORP	Breast Cancer	Active	Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion to Alliance Study A011502	III	384	0
41	WF-97415	WAKE	NCORP	Breast Cancer	Active	Understanding and Predicting Breast Cancer Events after Treatment (UPBEAT)	Other	1000	34*
42	EA5142	ECOG-ACRIN	NCTN	Lung, Mediastinal, and Pleural Cancer	Active	Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers	III	714	640
43	CITN-12	CITN	MISCELLANEOUS	AIDS-related Malignancy and Condition;Gastrointestinal Cancer;Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Lung, Mediastinal, and Pleural Cancer;Lymphoma;Miscellaneous and Metastatic Cancer;Skin Cancer	Active	Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm	I	39	34
44	NRG-CC003	NRG	NCORP	Lung, Mediastinal, and Pleural Cancer	Active	Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer	II/III	302	184
45	9899	LAO-MA036	ETCTN	Miscellaneous and Metastatic Cancer	Active	A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519M in Patients with Advanced Solid Tumors	I	37	29
46	10144	LAO-NCI	ETCTN	Urothelial/ Bladder Cancer	Active	A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma with DNA-Repair Defects	II	60	0
47	NRG-GY012	NRG	NCTN	Female Reproductive System Cancer	Active	A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer	II	120	40
48	S1706	SWOG	NCTN	Breast Cancer	Active	A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer	II	300	1
49	S1701	SWOG	NCTN	Lung, Mediastinal, and Pleural Cancer	Active	A Randomized Phase II Trial of Carboplatin-Paclitaxel with or Without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma	II	66	0
50	10136	LAO-TX035	ETCTN	Miscellaneous and Metastatic Cancer	Active	A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients with CCNE1 Amplification	II	32	1